Previous 10 | Next 10 |
2023-05-31 13:10:47 ET Gainers: Aridis Pharmaceuticals ( ARDS ) +130% . Marker Therapeutics MRKR +31% . SunCar Technology Group SDA +27% . T Stamp ( IDAI ) +25% . Inventiva ( IVA ) +19% . Eledon Pharmaceuticals ( ELDN ) +19% ...
2023-05-19 08:20:32 ET Foot Locker FL -25% after Q1 earning release . Phio Pharmaceuticals ( PHIO ) -12% . Infobird ( IFBD ) -12% . Alimera Sciences ( ALIM ) -11% . Enveric Biosciences ( ENVB ) -10% . Eledon Pharmaceuticals ( E...
2023-05-12 13:03:09 ET Eledon Pharmaceuticals, Inc. (ELDN) Q1 2023 Results Conference Call May 11, 2023 04:30 PM ET Company Participants Paul Little - Chief Financial Officer David-Alexandre Gros - Chief Executive Officer Steve Perrin - President and Chief Scient...
2023-05-11 16:14:13 ET Eledon Pharmaceuticals press release ( NASDAQ: ELDN ): Q1 GAAP EPS of -$0.75 misses by $0.11 . Eledon ended the first quarter with approximately $46.5 million in cash and cash equivalents, which excludes the $35.0 million received in the recent f...
Reported open-label data from ongoing Phase 1b trial of tegoprubart in kidney transplantation demonstrating mean eGFRs from 3 participants above 70 mL/min/1.73m 2 at measured timepoints Completed financing of up to $185 million, with $35 million upfront, to fund the Company ...
2023-05-10 14:45:46 ET Summary Tegoprubart has the potential to become the first-line immunomodulatory agent after kidney transplantation, a $375M/year U.S. revenue opportunity. The company has a negative enterprise value, so investors are ignoring the pipeline despite promising e...
IRVINE, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that it plans to release financial results for the first quarter ended March 31, 2023 on Thursday, May 11, after the close of trading. Eledon’...
2023-05-01 10:22:52 ET Eledon Pharmaceuticals ( NASDAQ: ELDN ) stock rose ~10% on Monday after the company said certain healthcare investors will provide up to $185M in gross proceeds via a private placement. The purchase consists of an initial upfront financing of $35M in e...
$35 million in upfront financing with the potential to receive additional aggregate financing up to $105 million, subject to achieving clinical development milestones, plus up to $45 million upon exercise of warrants Led by BVF Partners LP and Armistice Capital, with participation from ...
2023-03-31 06:32:57 ET Eledon Pharmaceuticals ( NASDAQ: ELDN ) reported data from an ongoing phase 1b trial of tegoprubart in patients undergoing kidney transplant and safety data from a phase 2a trial of tegoprubart in IgA Nephropathy (IgAN). The company presented data...
News, Short Squeeze, Breakout and More Instantly...
Eledon Pharmaceuticals Inc Com Company Name:
ELDN Stock Symbol:
NASDAQ Market:
Eledon Pharmaceuticals Inc Com Website:
IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that the Company’s management team will be hosting one-on-one meetings at the Leerink Partners Therapeutics Forum: I&I and Metabolism, on July 9, ...
Data from 13 participants presented at the American Transplant Congress continue to support safety and tolerability profile of tegoprubart Overall mean eGFR of all reported time points after day 30 post-transplant of 70.5 mL/min/1.73m² Mean eGFR measured above 60 mL/min/1.73m...